Belinostat (PXD101)

目录号:S1085 别名: NSC726630, PX-105684

Belinostat (PXD101) Chemical Structure

Molecular Weight(MW): 318.35

Belinostat (PXD101)是一种新型HDAC抑制剂,无细胞试验中IC50为27 nM,对耐Cisplatin的肿瘤具有活性。

规格 价格 库存 购买数量  
In DMSO RMB 1317.13 现货
RMB 981.69 现货
RMB 3030.32 现货
RMB 4653.78 现货
RMB 7950.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献40篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Belinostat (PXD101)是一种新型HDAC抑制剂,无细胞试验中IC50为27 nM,对耐Cisplatin的肿瘤具有活性。
特性 Belinostat是Topotarget的领先药物,已经进行过多次临床试验。
靶点
HDAC [1]
(Cell-free assay)
27 nM
体外研究

Belinostat抑制肿瘤细胞生长(包括A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3,及HS852),IC50为0.2到0.66 μM。Belinostat 作用于A2780/cp70 和2780AD细胞时活性很低, 这两个细胞是抗cisplatin和doxorubicin的A2780细胞衍生的。Belinostat通过PARP分裂和组蛋白H3/H4的乙酰化而诱导细胞凋亡。[1] Belinostat抑制膀胱癌细胞生长,尤其是5637细胞,细胞在G0-G1期积累, 在S期下降,在 G2-M期上升。[2] Belinostat抑制细胞生长的活性不受多重耐药表现型的影响, 但是docetaxel的活性明显受影响。Belinostat 可以增强docetaxel或carboplatin 抑制OVCAR-3和A2780细胞的活性。Belinostat作用于卵巢癌细胞系也增强微管乙酰化作用。[3] 最新研究显示 Belinostat在TGF-β信号依赖机制中激活蛋白激酶A 和降低survivin mRNA。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NB4 NIrMVYZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:wMlIwOsLizszN MnO0NlQwPDhxN{KgbC=> MkPy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MWiyOVg3PDd|Mh?=
HL-60  NFu2OodE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVXUb|JPOC5{L{NCpO69VQ>? NEexPYkzPC92OD:3NkBp M2jQcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MmiyNlU5PjR5M{K=
NB4 MUXGeY5kfGmxbjDBd5NigQ>? NUS5R5k1OsLizszN MV6yOE81QCCq NHjqfnNjdG:la4OgZ4VtdCCleXPs[UBqdiCVIIDoZZNm MY[yOVg3PDd|Mh?=
HL-60  MYnGeY5kfGmxbjDBd5NigQ>? NF7tfY0zyqEQvF2= MlO1NlQwPDhiaB?= MWHicI9kc3NiY3XscEBkgWOuZTDpckBUKHCqYYPl MUKyOVg3PDd|Mh?=
NB4 NXy3UWxXTnWwY4Tpc44hSXO|YYm= MnX3NE4zyqEQvF2= NXG5Rod4OjRxNEivO|IhcA>? NH7aOXRmdmijbnPld{BTSS2rbnT1Z4VlKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25? NUXwbpVQOjV6NkS3N|I>
HL-60  NV\lclN[TnWwY4Tpc44hSXO|YYm= NIribmExNjMEoN88US=> NHLHWlczPC92OD:3NkBp NVzDclFM\W6qYX7j[ZMhWkFvaX7keYNm\CCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w M2jy[|I2QDZ2N{Oy
PANC-1 MkH5SpVv[3Srb36gRZN{[Xl? MWqxNOKh|ryP M3\KcVIwPC94IHi= MYHEUXNQ Mk[xbY5lfWOnczDBUXBMKGGldHn2ZZRqd25? MlnqNlM4PDNzOUi=
PANC-1 Ml7FR4VtdCCYaXHibYxqfHliQYPzZZk> M1PVUlEwOTEEoN88US=> M1TJcFQ5KGh? M1nXcmROW09? NX;tVVN2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy Mm\pNlM4PDNzOUi=
PANC-1 NI\kZnFHfW6ldHnvckBCe3OjeR?= MYqxNOKh|ryP NGjzZnAzNzRiaB?= M3HIV2ROW09? NFzj[IpqdmO{ZXHz[ZMhcW62cnHj[YxtfWyjcjDSU3MhdGW4ZXy= NXfJdXNGOjN5NEOxPVg>
H1666 M2PxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NuKhcA>? MkD6SG1UVw>? NXvvbnNOUUN3ME6xNEDPxE1? MVmyN|UyPTd3Mh?=
H460 M1GxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O5clczyqCq MoHvSG1UVw>? NFrJdYFKSzVyPUCuPFYh|ryP Mo[zNlM2OTV5NUK=
H1299 M2r2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW3NuKhcA>? MV\EUXNQ MlL5TWM2OD1zLkKg{txO MXmyN|UyPTd3Mh?=
H520 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPRT3M4OsLiaB?= NVXvNlB7TE2VTx?= MXfJR|UxRTBwN{Wg{txO MYSyN|UyPTd3Mh?=
H1975 NWrnXY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnBeoxwPzMEoHi= M1LmW2ROW09? M{m5SmlEPTB;MD62PEDPxE1? MYGyN|UyPTd3Mh?=
H1650 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzJNVZGPzMEoHi= M{Dm[mROW09? M{XOOWlEPTB;MD64PEDPxE1? NFfuSlYzOzVzNUe1Ni=>
H820 NYfOd|NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG3NuKhcA>? M1TpWmROW09? NYLRNGN4UUN3ME2wMlQh|ryP NXO5RVI2OjN3MUW3OVI>
PC9 M3f1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDoO|LDqGh? Ml;nSG1UVw>? M3jSfWlEPTB;MD6yPUDPxE1? MW[yN|UyPTd3Mh?=
HCC2279 NHXSNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\IXJc4OsLiaB?= NUHZUnBVTE2VTx?= MYDJR|UxRTBwNDFOwG0> MU[yN|UyPTd3Mh?=
HCC827 M4DXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvEeJN{PzMEoHi= MXPEUXNQ MWfJR|UxRTBwMkmg{txO NUjmWYVwOjN3MUW3OVI>
HCC2935 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL1[WE4PzMEoHi= NF3I[IpFVVOR NUXCSFk4UUN3ME2wMlk4KM7:TR?= MnvvNlM2OTV5NUK=
HCC4006 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm3NuKhcA>? MorSSG1UVw>? M2Sye2lEPTB;MD60OkDPxE1? MlH4NlM2OTV5NUK=
H460 NUfGZWZUTnWwY4Tpc44hSXO|YYm= M3HIXVUxOMLibl2= NHTJNIozPMLiaB?= MkSxSG1UVw>? NVrkWFZz\GWlcnXhd4V{KEWJRmKg[ZhxemW|c3nvci=> M3zrflI{PTF3N{Wy
H1650 NXG2VXlPTnWwY4Tpc44hSXO|YYm= MWm1NFDDqG6P MX:yOOKhcA>? MmLCSG1UVw>? M2TJRoRm[3KnYYPld{BGT0[UIHX4dJJme3Orb36= MlziNlM2OTV5NUK=
PC9 NYq2R2N2TnWwY4Tpc44hSXO|YYm= MoP0OVAxyqCwTR?= NV3PbId1OjUEoHi= M1PBSWROW09? MlXE[IVkemWjc3XzJGVITlJiZYjwdoV{e2mxbh?= NFi0Rm0zOzVzNUe1Ni=>
H460 Mn;PSpVv[3Srb36gRZN{[Xl? NHvsWIwxNjVxMT:yJO69VQ>? NXjpNlR3PCCq M2\lTWROW09? MV7pcohq[mm2czD0bIUhdGW4ZXzzJI9nKEGtdDCodE1Cc3RrIHHu[EBGT0[U MUmyN|UyPTd3Mh?=
H1650 M3XWXWZ2dmO2aX;uJGF{e2G7 NELvU3oxNjVxMT:yJO69VQ>? NWjV[XRtPCCq M4[1cGROW09? MXfpcohq[mm2czD0bIUhdGW4ZXzzJI9nKEGtdDCodE1Cc3RrIHHu[EBGT0[U NHrFVFMzOzVzNUe1Ni=>
PC9 NXPoW5BrTnWwY4Tpc44hSXO|YYm= M3;yS|AvPS9zL{Kg{txO MUG0JIg> NI\MNmpFVVOR M{T3XolvcGmkaYTzJJRp\SCuZY\lcJMhd2ZiQXv0JEhxNUGtdDmgZY5lKEWJRmK= MWCyN|UyPTd3Mh?=
AsPc1 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HXeFQ5KGh? MXTFR|UxRTBwMzFOwG0> M{niSVI{PDd3Nkm1
Panc0327 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDqNGFbPDhiaB?= Mmi0SWM2OD1yLkWg{txO NELGWpkzOzR5NU[5OS=>
MiaPaCa2 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK0PEBp NGXyZ2xGSzVyPUCuO{DPxE1? MXWyN|Q4PTZ7NR?=
BxPc3 NYPzPI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe0PEBp MnvhSWM2OD1zLkCg{txO NEXSPJEzOzR5NU[5OS=>
Panc0403 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf0W4Y6PDhiaB?= NG[3Z4pGSzVyPUGuNUDPxE1? MXuyN|Q4PTZ7NR?=
Panc1005 NXqyZYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrMOFghcA>? MmDBSWM2OD1zLkGg{txO M37Nb|I{PDd3Nkm1
PL45 NYHTeFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTFOFghcA>? NHrHdGVGSzVyPUKwMlgh|ryP MXiyN|Q4PTZ7NR?=
Panc0203 NHjBcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPMOWc1QCCq M3raW2VEPTB;MkKuNkDPxE1? MYqyN|Q4PTZ7NR?=
Panc0327 NVnWUJY2SXCxcITvd4l{KEG|c3H5 M{fmZlEh|ryP M2DXT|I1KGh? MWTpcoR2[2W|IHHwc5B1d3Orcx?= NXq1W4x6OjN2N{W2PVU>
Panc1005 M{P1VWFxd3C2b4Ppd{BCe3OjeR?= NV3aUGVGOSEQvF2= M4jRS|I1KGh? NYPMO2kycW6mdXPld{BieG:ydH;zbZM> NEfHUIszOzR5NU[5OS=>
Panc0403 NF;jclBCeG:ydH;zbZMhSXO|YYm= MUSxJO69VQ>? MlP4NlQhcA>? NXLUeIJncW6mdXPld{BieG:ydH;zbZM> MkWzNlM1PzV4OUW=
AsPc1 NVzqdFJETnWwY4Tpc44hSXO|YYm= MonRNU8yOCEQvF2= NYPnWHBNOjRiaB?= MUnpcoR2[2W|IDDndo94fGhiYYLy[ZN1\WRiaX6gS|IwVQ>? M{T2blI{PDd3Nkm1
MiaPaCa2 MUnGeY5kfGmxbjDBd5NigQ>? MW[xM|ExKM7:TR?= MlzENlQhcA>? M3npN4lv\HWlZYOgJIdzd3e2aDDhdpJme3SnZDDpckBIOi:P MVmyN|Q4PTZ7NR?=
T3M4 NWi2[VJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PYRVAuQDByIH7N M1TiSVQ5KGh? MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NVvwbItTOjJ4OEG2PVg>
AsPC-1 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLCWWZzOC16MECgcm0> NVPncWNqPDhiaB?= NWLxdG5FcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIK5TFczOjZ6MU[5PC=>
Panc-1  M{WzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrFNE05ODBibl2= MlfyOFghcA>? M1TURolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXv3cYZvOjJ4OEG2PVg>
T3M4 MmjnRZBweHSxc3nzJGF{e2G7 NVvLZ4wzOTByL{WwNE8yODByIH7N MVK0PEBp MnXibY5lfWOnczDkc5NmKGSncHXu[IVvfCCjcH;weI9{cXN? NG\0VHkzOjZ6MU[5PC=>
AsPC-1 MlrNRZBweHSxc3nzJGF{e2G7 Ml\KNVAxNzVyMD:xNFAxKG6P M4rYWFQ5KGh? MXzpcoR2[2W|IHTvd4Uh\GWyZX7k[Y51KGGyb4D0c5Nqew>? M{ToflIzPjhzNkm4
Panc-1  MnnORZBweHSxc3nzJGF{e2G7 M37oeFExOC93MECvNVAxOCCwTR?= NF3nc5Q1QCCq NV\wdo9DcW6mdXPld{Bld3OnIHTldIVv\GWwdDDhdI9xfG:|aYO= NULtcYNOOjJ4OEG2PVg>
HBL-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TO[|I1KGh? NULTe4RsUUN3ME2wMlQh|ryP MoWzNlAxPjhyOEC=
Jeko-1 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1frS|I1KGh? NECyfXpKSzVyPUCuNkDPxE1? MXWyNFA3QDB6MB?=
Granta-519 MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSyOEBp MVzJR|UxRTV4LkOg{txO NXTUOpZtOjByNkiwPFA>
HCT116 NG\HN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPaNoU1QCCq M2XFNGVEPTB;MD6yPEDPxE1? M3fQNlE4OTJ2NUm0
HCT116 M1XBc2Z2dmO2aX;uJGF{e2G7 NF7H[YsxNjoEoN88UeKh MY[yOEBp M1nNfYRwf25vcnXneYxifHNiVGOgdJJwfGWrbjDs[ZZmdHNiYX\0[ZIhPsLiaDDpcoN2[mG2aX;u M1zOWFE4OTJ2NUm0

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / p-ERK / p-p38 / p38 / p-BRAF / p-MEK / MEK ; 

PubMed: 28397399     


Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (0.1, 0.2, 0.3, 1, 3 μm). Immunoblotting was performed to evaluate the changes in phosphorylated protein levels of the targets identified in 1D (ERK1/2, p38, B‐Raf, MEK1/2) as well as PARP. β‐Actin shown as loading control. 

SOS1 / SOS2; 

PubMed: 28397399     


(A) Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (PXD101) (0.1, 0.2, 0.3, 1, 3 μm) to evaluate the changes in SOS1 and SOS2. 

p21 / p27 ; 

PubMed: 23982416     


(A and B) The cell lines shown were treated with PXD101 for 0, 2, 4, 8, 24, 48, and 72 h. Whole cell extracts were generated and subjected to western blotting with antibodies against p21, p27, hsp90, α-tubulin, or GAPDH. PXD101-resistant cell lines are shown in (A, left) while PXD101-sensitive cell lines are shown in (B, right). 

Acetyl Histone H3 / Acetyl Histone H4 / Acetyl tubulin; 

PubMed: 24155971     


PXD101 induced acetylation of histone H3 and histone H4 in a dose-dependent manner. PXD101 also increased acetylation of tubulin in BHP7-13, WRO82-1 and 8505C.

p-H2AX(Ser139) / KU70 / KU80 / RAD51 / RAD52 / ERCC1 ; 

PubMed: 24155971     


increasing doses of PXD101 enhanced degradation of KU70, KU80 and RAD51, and enhanced expression of p-H2AX (Ser139), RAD52 and ERCC1 in BHP7-13, WRO82-1 and 8505C.

28397399 23982416 24155971
Growth inhibition assay
IC50; 

PubMed: 28397399     


Lung SCC cell lines and normal lung fibroblast cell lines were treated with belinostat (PXD101) for 72 h, and cell viability was determined with CellTiter assay. Data are represented as mean IC50 ± SD (n = 3).

Cell viability; 

PubMed: 24155971     


Dose-response curves were obtained on day 4 from cells treated with a series of six 1:1 dilutions of PXD101. 

28397399 24155971
体内研究 Belinostat按10mg/kg剂量处理A2780和A2780/cp70 移植瘤,明显延迟肿瘤生长,但是对动物体重没有影响。[1] 在鼠膀胱细胞中,Belinostat也诱导p21WAF1, HDAC 核心和细胞通讯基因。[2] Belinostat按100mg/kg剂量单独处理A2780移植瘤,产生抗癌功效,肿瘤抑制率(TGI)达47% ,这种抑制存在剂量依赖性。100 mg/kg Belinostat和40 mg/kg Carboplatin联用可以延迟肿瘤生长,从18.6 天到22.5 天。 [3] Bortezomib和Belinostat联用,明显抑制肿瘤,此外,作用于携带抗Bortezomib UMSCC-11A移植瘤的鼠显示肠胃毒性 。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

组蛋白脱乙酰基酶活性实验:

汇合培养,用冷PBS中冲洗2遍,按200×g 转速离心5分钟。 细胞悬浮在2体积的溶解 buffer 中,60 mm Tris buffer (pH 为7.4)包含30%甘油和450 mm NaCl,用干冰冻结,然后30oC水浴溶解,循环3次。细胞碎片按1.2×104g转速离心5分钟, 然后上清液储存于−80oC中。使用 [3H]乙酰 CoA,通过p300的重组蛋白包括次黄嘌呤-氨基喋呤-胸腺嘧啶域乙酰化组蛋白H4肽段 (序列为SGRGKGGKGLGKGGAKRHRK)。100 μg H4 肽段与次黄嘌呤-氨基喋呤-胸腺嘧啶buffer(buffer包含50 mM Tris HCl pH为8.0, 5% 甘油, 50 mM KCl, 和0.1 mM EDTA),1 mM DTT, 1 mM 4-(2-氨乙基) ,苯磺酰基氟化物, 1×蛋白酶抑制剂, 50 μL纯化的p300, 及1.85 m [3H]乙酰 CoA (4.50Ci/mmol)混合,最终体积为300 μL,在30oC温育45分钟。p300蛋白 和 20 μL 50% Ni-琼脂糖在4oC下温育1小时,然后离心分离。上清液上样到2 mL Sephadex G15 柱中。加入1毫升蒸馏水,收集三滴样片,重复加入蒸馏水直到体积为4-5 mL,收集40滴样片。用2 mL 闪烁液稀释3微升样片,在闪烁计数板上计数,用于鉴定包含标记肽段的样片。合并样片,测定1 μL组合样本,用于测定每个肽段的放射性。在150 μL buffer,2 μL 细胞抽提物,和2 μL Belinostat的混合液中进行反应。加入2 μL [3H] 标记的底物开始反应。样本在 37oC下温育45分钟,加入HCl 和乙酸(终浓度分别为0.72和0.12 M)终止反应。释放的[3H]乙酸盐加到750 μL of 乙酸乙酯中, 按1.2×104g转速 离心5分钟。上层 (600 μL) 转移到3 mL闪烁液,然后计数。
细胞实验:[1]
+ 展开
  • Cell lines: A2780, A2780/cp70, 2780AD, HCT116, HT29, WIL, CALU-3, MCF7, PC3,和HS852细胞
  • Concentrations: 0.016到10 μM
  • Incubation Time: 24小时
  • Method: 肿瘤细胞系(A2780, A2780/cp70, 2780AD, HCT116, HT29, WIL, CALU-3, MCF7, PC3,和HS852) 按8×104个细胞/25 cm2 瓶接种在5 mL 培养基中,温育48小时。用Belinostat (0.016 到 10 μm)处理细胞24小时。1 mL 胰蛋白酶/EDTA加到培养瓶中。细胞分离后,加入1 mL培养基,细胞再次悬浮。稀释细胞,按0.5-2×103个细胞/皿移到6cm Petri皿中。37oC下温育10到15天。用PBS冲洗细胞,溶于甲醇,用结晶紫染色,计数大于50个细胞的群落。通过IC50值计算敏感度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 右侧腹皮下注射A2780, A2780/cp70和HCT116细胞的CD1 nu/nu鼠
  • Formulation: Belinostat 溶解在DMSO中,然后用水稀释,最终浓度10%
  • Dosages: ≤40 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 64 mg/mL (201.03 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 318.35
化学式

C15H14N2O4S

CAS号 414864-00-9
储存条件 powder
in solvent
别名 NSC726630, PX-105684

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03772925 Recruiting Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome National Cancer Institute (NCI) February 28 2019 Phase 1
NCT02680795 Recruiting Solid Tumors|Hematological Malignancies Acrotech Biopharma LLC|Axis Clinicals Limited March 2016 Phase 1
NCT02679131 Terminated Relapsed/Refractory Solid Tumors/Hematological Malignancies Acrotech Biopharma LLC|Axis Clinicals Limited March 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you please give some suggestions for the use of Belinostat in vivo (i.p. injection)?

  • 回答:

    For I.P. injection, S1085 Belinostat (PXD101) can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water. Hope this information is useful to you.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Belinostat (PXD101) | Belinostat (PXD101)供应商 | 采购Belinostat (PXD101) | Belinostat (PXD101)价格 | Belinostat (PXD101)生产 | 订购Belinostat (PXD101) | Belinostat (PXD101)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID